Finding the Positives in Triple-Negative Breast Cancer:

Transcription

1 Finding the Positives in Triple-Negative Breast Cancer: A Three-Part Live CME Webcast Series Seminar I Wednesday, March 3, 2010 Faculty Clifford Hudis, MD Lisa A Carey, MD Seminar II Thursday, March 11, 2010 Faculty Jenny C Chang, MD Joyce O Shaughnessy, MD Seminar III Tuesday, March 16, 2010 Faculty Kathy D Miller, MD Hope S Rugo, MD Moderator for all three events: Register at w w w.researchtopr ac tice.com /Meetings / TNBC2010 CME Certified Sponsored by Research To Practice. These events are supported by an educational grant from Sanofi-Aventis. Copyright 2010 Research To Practice. From the publishers of:

2 Faculty Moderator Editor, Breast Cancer Update Audio Series Research To Practice Miami, Florida Wednesday March 3, 2010 Clifford Hudis, MD Chief, Breast Cancer Medicine Service, Solid Tumor Division Department of Medicine Memorial Sloan-Kettering Cancer Center New York, New York Lisa A Carey, MD Medical Director, UNC Breast Center, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina Thursday March 11, 2010 Jenny C Chang, MD Dan L Duncan Professor Lester and Sue Smith Breast Center Baylor College of Medicine Houston, Texas Joyce O Shaughnessy, MD Co-Director, Breast Cancer Research Program, Baylor-Charles A Sammons Cancer Center Texas Oncology, PA US Oncology Dallas, Texas Tuesday March 16, 2010 Kathy D Miller, MD Sheila D Ward Scholar of Medicine Associate Professor of Medicine The Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana Hope S Rugo, MD Clinical Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center San Francisco, California

3 Program Overview This unique three-part, online, integrated educational course was designed to provide an array of perspectives relevant to the current and future treatment of triple-negative breast cancer (TNBC). This series will consist of three 60-minute virtual educational seminars broadcast live via the web. Two faculty members will participate in each seminar remotely from their home city using web-based video technology. From our studio in Miami, I will moderate each session, which will feature a mix of didactic presentations and discussion. Learners watching the activity live will have the opportunity to submit questions via audio or text during the broadcast, which will be integrated in real time into the proceedings. These seminars will provide pertinent information that medical oncologists and other allied cancer professionals can use to make up-to-date and appropriate treatment decisions that lead to improved care for patients with TNBC. I hope you will consider joining us for one or more of these interesting events. Editor, Breast Cancer Update Audio Series Miami, Florida Submit questions or cases for discussion during the live webcast This three-part series will allow viewers to actively engage in the proceedings. As such, viewers will be able to submit questions or cases to the faculty panel and moderator for discussion during each of the live webcasts.

4 A Three-Part Live CME Webcast Series on Triple-Negative Breast Cancer Seminar I Wednesday March 3, 2010 Module 1 (Dr Hudis) Breast cancer demographics based on ER, PR and HER2 phenotype Presenting stage and prognosis of triple-negative breast cancer (TNBC) Sites of metastatic disease Potential heterogeneity of TNBC: Example Targeting the androgen receptor-positive subset Seminar II Thursday March 11, 2010 Module 3 (Dr Chang) Major mechanisms of DNA repair: Recombinational repair, nucleotide excisions repair, base excision repair, mismatch repair, direct reversal Mechanisms of action of PARP inhibitors BRCA mutations and DNA repair Synthetic lethality Seminar III Tuesday March 16, 2010 Module 5 (Dr Miller) New pathways and novel agents in TNBC Met activation and amplification: Trials evaluating Met inhibitors Nm23-H1 metastases suppressor gene; trials of medroxyprogesterone acetate (MPA) to stimulate production Module 2 (Dr Carey) Intrinsic subtypes of breast cancer - Challenges in classification - Overlap of TNBC and basal subtype - Clinical and research implications of BC subtypes BRCA mutations and BRCAness Claudin-low subtype Module 4 (Dr O Shaughnessy) PARP inhibitors: - Method of administration - Tolerability alone and with chemotherapy Clinical trials of PARP inhibitors in TNBC Updated results of the Phase II randomized trial of carboplatin/ gemcitabine alone or with BSI-201 Module 6 (Dr Rugo) Neoadjuvant and adjuvant therapy Systemic therapy for metastatic disease - Ixabepilone - Bevacizumab and other anti-angiogenic strategies - Platinum agents

5 CME Information Target Audience: This activity has been designed to meet the educational needs of medical oncologists, oncology fellows and other healthcare providers involved in the treatment of breast cancer. Learning Objectives: Upon completion of this activity, participants should be able to: Compare and contrast the molecular and clinical features of triple-negative, basal-like and BRCA1-deficient breast tumors. Recognize the pathologic commonalities among triplenegative and BRCA1/2 mutated breast cancer that confer selective sensitivity to therapeutic inhibition on PARP-1. Communicate the prognostic implications of the triplenegative phenotype and its impact on selection of available treatment approaches. Describe the relative chemosensitivity of TNBC and identify opportunities to maximize cytotoxic effects. Recall the scientific basis for investigation of angiogenesis inhibitors, PARP inhibitors and other novel agents as targeted treatment of TNBC. Develop a therapeutic algorithm for the current evidencebased treatment of TNBC. Counsel appropriately selected patients about availability and participation in ongoing clinical research studies focusing on the management of early and advanced TNBC. CME Credit Form: A link to the credit form will be provided to each participant at the conclusion of each activity. Accreditation Statement: Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement: Research To Practice designates each educational activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in each of the activities. Disclosure Policy: As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/ unapproved uses of drugs or devices will be provided in meeting course materials.

6 Register Today Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL PRESORTED FIRST-CLASS U.S. POSTAGE PAID MIAMI, FL PERMIT #1317 All events are free of charge, but registration is required. Once you register, you will receive an with specific log-in instructions to follow on the webcast viewing day. If you are registering a group (more than one person) for these events, please us at Meetings@ResearchToPractice.com or call (800)